EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Lacticaseibacillus rhamnosus GG in a chewable colonizes the nose and facilitates local immune benefits in allergic rhinoconjunctivitis patients

Ilke De Boeck iD, Irina Spacova iD, Eline Cauwenberghs, Tom Eilers, Thies Gehrmann, Karlien Van den Bossche, Katleen Martens, Sandra Condori-Catachura, Kato Michiels, Fien De Winter, Samir Kumar-Singh, Nicolas Bruffaerts und 6 weitere

Microbiology Spectrum · 07.10.2025 · 13 (10)

DOI: 10.1128/spectrum.00773-25 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Microbiology Spectrum, erschienen am 07.10.2025. Verfasst von Ilke De Boeck und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Applied Microbiology and Biotechnology, Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium. Hauptthemen laut MEDLINE: Lacticaseibacillus rhamnosus, Probiotics, Rhinitis, Allergic, Seasonal, Nose. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek, iBOF, European Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current treatments fall short in managing allergic rhinitis (AR), emphasizing the need for additional strategies. Beneficial bacteria application shows promise in AR; however, most studies focus on oral probiotic administration without monitoring the applied strains in the upper respiratory tract (URT) and their local effects. In this randomized, double-blind, placebo-controlled trial, the probiotic Lacticaseibacillus rhamnosus GG was administered via chewable tablets in seasonal AR patients, randomized to probiotic ( n = 33) or placebo ( n = 31) groups. Per-protocol analysis of the URT microbiome, immune markers, and AR symptoms was performed. L. rhamnosus GG trafficked from chewables to the oropharynx (77%, P = 0.02) and nasopharynx (41%, P < 0.0001). Control of self-reported AR symptoms via validated questionnaires under grass pollen exposure was observed after 2 weeks of probiotic administration and not upon placebo. A local decrease in salivary interleukin-4 ( P < 0.05) and nasal IL-13 ( P < 0.0001) was observed in the probiotic group. These data indicate that L. rhamnosus GG chewables can target the URT and exert local effects on key allergy cytokines after temporal probiotic engraftment. IMPORTANCE Allergic rhinitis (AR) or hay fever is a highly prevalent condition, impacting nearly half the population in some countries. Supplementation of beneficial bacteria or probiotics has gained increasing attention in AR, and a key innovative way to do this is direct administration to the upper airways. Our study shows for the first time that the model probiotic strain Lacticaseibacillus rhamnosus GG can traffic to the nose in AR patients when administered via a slow-releasing chewable tablet. This trafficking is associated with local benefits in the airways, including on grass pollen-induced nasal symptoms and allergy-related cytokines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lacticaseibacillus rhamnosusProbioticsRhinitis, Allergic, SeasonalNoseRhinitis, AllergicHumansAdultDouble-Blind MethodMaleFemaleMiddle AgedYoung AdultPollen

Stichwörter der Autor:innen

Lacticaseibacillusallergyhuman microbiomeprobiotics

Autor:innen und Institutionen

  • Laboratory of Applied Microbiology and Biotechnology, Department of Bioscience Engineering, University of Antwerp, Antwerp, Belgium.
  • Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.
  • ENT, Head and Neck Surgery, Antwerp University Hospital, Edegem, Belgium.
  • Department of Microbiology, Immunology and Transplantation, Allergy and Clinical Immunology Research Group, KU Leuven, Leuven, Belgium.
  • Data Science Institute and I-BioStat, Hasselt University, Diepenbeek, Belgium.
  • Molecular Pathology Group, Laboratory of Cell Biology & Histology, Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium.

ORCID-Profile: Ilke De Boeck, Irina Spacova, Sarah Lebeer

Förderung

  • Fonds Wetenschappelijk Onderzoek
  • iBOF
  • European Research Council

Zitieren

APA

De Boeck, I., Spacova, I., Cauwenberghs, E., Eilers, T., Gehrmann, T., Van den Bossche, K., Martens, K., Condori-Catachura, S., Michiels, K., De Winter, F., Kumar-Singh, S., Bruffaerts, N., Packeu, A., Hellings, P. W., Vroegop, A., Van Gool, K., Vanderveken, O. M., & Lebeer, S. (2025). Lacticaseibacillus rhamnosus GG in a chewable colonizes the nose and facilitates local immune benefits in allergic rhinoconjunctivitis patients. Microbiology Spectrum, 13(10). https://doi.org/10.1128/spectrum.00773-25

Vancouver

De Boeck I, Spacova I, Cauwenberghs E, Eilers T, Gehrmann T, Van den Bossche K, et al. Lacticaseibacillus rhamnosus GG in a chewable colonizes the nose and facilitates local immune benefits in allergic rhinoconjunctivitis patients. Microbiology Spectrum. 2025;13(10). doi:10.1128/spectrum.00773-25

BibTeX
@article{DeBoeck2025,
  author = {De Boeck, Ilke and Spacova, Irina and Cauwenberghs, Eline and Eilers, Tom and Gehrmann, Thies and Van den Bossche, Karlien and Martens, Katleen and Condori-Catachura, Sandra and Michiels, Kato and De Winter, Fien and Kumar-Singh, Samir and Bruffaerts, Nicolas and Packeu, Ann and Hellings, Peter W and Vroegop, Anneclaire and Van Gool, Klara and Vanderveken, Olivier M and Lebeer, Sarah},
  title = {Lacticaseibacillus rhamnosus GG in a chewable colonizes the nose and facilitates local immune benefits in allergic rhinoconjunctivitis patients},
  journal = {Microbiology Spectrum},
  year = {2025},
  volume = {13},
  number = {10},
  doi = {10.1128/spectrum.00773-25}
}
Kostenlos starten →